MARKET

AVDL

AVDL

Avadel Pharmaceu
NASDAQ
15.22
-0.05
-0.33%
After Hours: 15.63 +0.41 +2.69% 16:33 06/12 EDT
OPEN
15.49
PREV CLOSE
15.27
HIGH
16.05
LOW
15.21
VOLUME
1.05M
TURNOVER
0
52 WEEK HIGH
19.09
52 WEEK LOW
9.50
MARKET CAP
1.46B
P/E (TTM)
-8.1903
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at AVDL last week (0603-0607)?
Weekly Report · 3d ago
Weekly Report: what happened at AVDL last week (0527-0531)?
Weekly Report · 06/03 10:06
Weekly Report: what happened at AVDL last week (0520-0524)?
Weekly Report · 05/27 10:08
Avadel Pharmaceuticals Shares New LUMRYZ For Extended-Release Oral Suspension Data At SLEEP 2024 June 1-5, 2024
Avadel Pharmaceuticals plc will present 11 posters supporting the use of LUMRYZ as a narcolepsy treatment option at SLEEP 2024. Avadel will present at the 38th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society in Houston.
Benzinga · 05/22 12:13
AVADEL PHARMACEUTICALS APPOINTS NASEEM AMIN, M.D. TO ITS BOARD OF DIRECTORS
Reuters · 05/21 11:00
Weekly Report: what happened at AVDL last week (0513-0517)?
Weekly Report · 05/20 10:05
Avadel gains for a second day as analysts see it prevailing in case vs Jazz/FDA
Avadel Pharmaceuticals (AVDL) has gained 17% over the past two trading sessions. The company is in a patent dispute with Jazz Pharmaceuticals over a sleep disorder drug. An analyst says he is 75% confident Avadel will prevail in the case against Jazz/FDA.
Seeking Alpha · 05/13 19:34
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Akero Therapeutics (AKRO) and Madrigal Pharmaceuticals (MDGL)
TipRanks · 05/13 12:01
More
About AVDL
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Webull offers Avadel Pharmaceuticals PLC (ADR) stock information, including NASDAQ: AVDL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVDL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVDL stock methods without spending real money on the virtual paper trading platform.